Director + Member, Science and Technology Committee Dr. Jacob has over 35 years of extensive experience in the pharmaceutical and biotechnology industries across multiple disciplines, including research and development, operations, business development, capital financing activities and senior management expertise. He is the Co-Founder and former CEO and Chairman of Synergy Pharmaceuticals and has developed broad and influential contacts throughout the biopharmaceutical, financial, banking and investor communities. He served as Chairman, Chief Executive Officer and a Director at Synergy Pharmaceuticals Inc. from July 2008 until October 2017 and is the co-inventor of the FDA-approved drug Trulance ® which is currently marketed in the U.S. by Bausch Health, Inc. to treat functional GI disorders. Dr. Jacob is also the former CEO and Managing Director of Immuron Inc., an Australian biotechnology company dual-listed on the Australian ASX exchange and on NASDAQ. Dr. Jacob currently is Chairman of the Board of Hepion Pharmaceuticals, Inc., a public NASDAQ listed company with a drug in clinical development to treat nonalcoholic steatohepatitis (NASH), and also is on the Board of Directors of Trovagene, Inc., a NASDAQ listed public oncology company. He served as Chief Executive Officer and Director of Callisto Pharmaceuticals, Inc. from May 2003 until January 2013. Prior to his involvement with Callisto and Synergy, Dr. Jacob spent a number of years at Monsanto/G.D. Searle, where he was Director of Glycobiology and a Monsanto Science Fellow, specializing in the field of Glycobiology and drug discovery. Dr. Jacob holds over 15 patents and is the co-inventor of two FDA-approved pharmaceutical drugs. Dr. Jacob earned a B.S. in Chemistry cum laude from the University of Missouri – St. Louis and holds a Ph.D. in Biochemistry from the University of Wisconsin-Madison.

Director + Chairman, Audit Committee Mr. Jerrold Sendrow has been a Certified Financial Planner since 1986, and maintains a moderate practice. Mr. Sendrow also served as an outside Director on the Board of Directors of SCILEX Pharmaceuticals Inc. from 2014 to 2016. In addition, up through 2014, Mr. Sendrow has more than 35 years of experience as Chief Financial Officer and Director in companies with revenues in excess of $500 million. Jerry has led these companies through start-up, survival, turnaround and growth modes. Prior to that, Mr. Sendrow was an accountant in the audit departments of Touche Ross & Co. and Peat Marwick Mitchell & Co after returning from military service of two tours in the Vietnam conflict. Mr. Sendrow holds business degrees from Bernard Baruch College of the City University of New York and Adelphi University.

Director + Chairman, Scientific and Regulatory Advice Committee Dr. Eric Floyd currently serves as Chief Regulatory Officer at Neurogene Inc. He has nearly 21 years of regulatory experience within the pharmaceutical industry. Most recently, he was Senior Vice President, Regulatory Affairs, for Axovant Sciences. He served as President of Compliance Services and Chief Scientific Officer at Dohmen Life Science Services, Inc., Senior Vice President, US Regulatory Affairs and Clinical Quality Compliance at Lundbeck Inc., Global Vice President of Regulatory Affairs at Hospira, Vice President of Worldwide Regulatory Affairs and Quality Assurance at Cephalon and VP and Global Head of Respiratory, Dermatology, and Tropical Medicines Drug Regulatory Affairs at Novartis and held senior leadership roles at Bristol Myers Squibb, Aventis and Merck Research Laboratories. Dr. Floyd received a Ph.D. in Neurophysiology from Meharry Medical College, Nashville, an executive MBA from St. Joseph’s University, Philadelphia, an MS from Tennessee State University, a BS from the University of Illinois and has served as an Assistant Professor at Harvard University School of Medicine. Dr. Floyd served as an outside director on the Board of Directors of SCILEX Pharmaceuticals Inc. from 2014 to 2016.

EVP, Commercial Operations Gerald W. Bruce has spent over 30 years, including 20 years in senior leadership roles, in the Pharmaceutical and Medical Nutrition industry. He started his career at Johnson and Johnson where he was an award-winning sales representative and held leadership positions of increasing responsibility in sales and marketing ending with his role as Group Product Director of Analgesics. He then served as Vice President of Sales at Bristol-Myers Squibb where he led the Cardiovascular and Metabolic sales force responsible for over $1.2 Billion in sales. He later served as Vice President of Managed Markets where he led the team responsible for the development and implementation of the reimbursement strategy for the Bristol-Myers Squibb $7 billion US portfolio. Mr. Bruce went on to become the Senior Vice President of Commercial Operations at NitroMed where he was responsible for building the commercial strategy and led the team responsible for the development and implementation of the commercial plan for the start-up company’s first product for the treatment of Heart Failure. He also spent close to ten years in the Medical Nutrition industry where he was Vice President of Sales for Nutricia North America, Danone Medical Nutrition Division. Mr. Bruce currently serves on the Board of Trustees for Lincoln University and is a Board member for the National Sales Network. He received his bachelor’s degree in Business Administration from Lincoln University and a master’s degree in Leadership from the McDonough School of Business at Georgetown University.

EVP, Chief Medical Officer Jeffrey Gudin, MD, was Director of Pain Management and Palliative Care at Englewood Hospital and Medical Center in New Jersey for almost 20 years. He is a Clinical Associate Professor in Anesthesiology at the Rutgers New Jersey Medical School. Dr. Gudin is Board Certified in Pain Medicine, Anesthesiology, Addiction Medicine and Hospice and Palliative Medicine. He is an active speaker in the field of pain management. His clinical and research focus includes pain management, opioid abuse and potential solutions, and increasing clinician awareness of pain assessment and risk management. Dr. Gudin completed a residency in anesthesiology at Yale University School of Medicine, in New Haven, Connecticut. He continued his training with an extended postdoctoral fellowship in pain medicine at the Yale Center for Pain Management, where he was actively involved in research and teaching.

Chairman + CEO Anthony P. Mack has more than 25 years of experience in the pharmaceutical and finance industries. Prior to founding VIRPAX in 2016, Mr. Mack founded SCILEX Pharmaceuticals and served as President and CEO until ZTlido was approved in February 2018. Mr. Mack founded his first pharmaceutical company ProSolus Pharmaceuticals in 2009, where he served as President before selling the company to Mission Pharmacal in 2015. Mr. Mack has held high-level management positions with Purdue Pharma, Endo Pharmaceuticals, Novartis, and EKR Therapeutics. He has led training, marketing, and commercial distribution for billion-dollar pain management products and has forged key strategic alliances. Mr. Mack has served as Founder, Director, and Executive Officer of both ProSolus Pharmaceuticals Inc. and SCILEX Pharmaceuticals. After SCILEX's lead product, ZTlido, was approved for commercialization by the FDA, SCILEX was sold to a publicly traded company. Mr. Mack also founded and serves as Director of IACTA Pharmaceuticals Inc. By serving on executive boards, Mr. Mack has utilized his skills and experience to implement policies relating to corporate governance and overall business strategy. Mr. Mack holds an Executive MBA in Pharmaceutical and Healthcare Marketing from Saint Joseph’s University.

FAQs – Virpax Pharmaceuticals

VANILA M. SINGH, MD, MACM

admin2020-07-07T09:49:48-04:00July 7th, 2020|Board|

Director Dr. Singh was the immediate past Chief Medical Officer in the US Department of Health and Human Services (“HHS”). She served as the Chairperson of the highly regarded HHS Task Force in conjunction with the Department of Defense and [...]

> Read More

GARY S. JACOB, PhD

admin2020-04-24T10:37:40-04:00April 23rd, 2020|Board|

Director + Member, Science and Technology Committee Dr. Jacob has over 35 years of extensive experience in the pharmaceutical and biotechnology industries across multiple disciplines, including research and development, operations, business development, capital financing activities and senior management expertise. He [...]

> Read More

THANI JAMBULINGAM, PhD

admin2020-02-11T20:09:39-05:00February 11th, 2020|Board|

Director + Chairman, Corporate Governance Dr. Thani Jambulingam is a Pfizer Fellow and Professor in the Department of Pharmaceutical and Healthcare Marketing at St Joseph’s University, Erivan K. Haub School of Business, in Philadelphia, Pennsylvania, USA. He teaches in the [...]

> Read More

JERROLD SENDROW, CFP

admin2020-02-11T20:09:17-05:00February 11th, 2020|Board|

Director + Chairman, Audit Committee Mr. Jerrold Sendrow has been a Certified Financial Planner since 1986, and maintains a moderate practice. Mr. Sendrow also served as an outside Director on the Board of Directors of SCILEX Pharmaceuticals Inc. from 2014 [...]

> Read More

ERIC FLOYD, PhD

admin2020-02-11T20:08:56-05:00February 11th, 2020|Board|

Director + Chairman, Scientific and Regulatory Advice Committee Dr. Eric Floyd currently serves as Chief Regulatory Officer at Neurogene Inc. He has nearly 21 years of regulatory experience within the pharmaceutical industry. Most recently, he was Senior Vice President, Regulatory [...]

> Read More

CHRISTOPHER M. CHIPMAN, CPA

admin2020-05-01T09:53:15-04:00February 11th, 2020|Executive|

Chief Financial Officer Christopher M. Chipman has been a managing member of Chipman & Chipman, LLC, since November 2000, a consulting firm that assists public companies with the preparation of periodic reports required to be filed with the Securities and [...]

> Read More

GERALD W. BRUCE

admin2020-02-23T14:42:24-05:00February 11th, 2020|Executive|

EVP, Commercial Operations Gerald W. Bruce has spent over 30 years, including 20 years in senior leadership roles, in the Pharmaceutical and Medical Nutrition industry. He started his career at Johnson and Johnson where he was an award-winning sales representative [...]

> Read More

JEFFREY GUDIN, MD

admin2020-02-23T14:42:14-05:00February 11th, 2020|Board, Executive|

EVP, Chief Medical Officer Jeffrey Gudin, MD, was Director of Pain Management and Palliative Care at Englewood Hospital and Medical Center in New Jersey for almost 20 years. He is a Clinical Associate Professor in Anesthesiology at the Rutgers New [...]

> Read More

ANTHONY P. MACK, MBA

admin2020-02-23T14:42:10-05:00February 11th, 2020|Board, Executive|

Chairman + CEO Anthony P. Mack has more than 25 years of experience in the pharmaceutical and finance industries. Prior to founding VIRPAX in 2016, Mr. Mack founded SCILEX Pharmaceuticals and served as President and CEO until ZTlido was approved [...]

> Read More